Cargando…

A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix

Nonalcoholic fatty liver disease, a type of metabolic syndrome, continues to rise globally. Currently, there is no approved drug for its treatment. Improving lifestyle and exercise can alleviate symptoms, but patients' compliance is poor. More and more studies have shown the potential of Polygo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mengting, Hu, Naihua, Liu, Meichen, Deng, Ying, He, Linfeng, Guo, Chaocheng, Zhao, Xingtao, Li, Yunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193283/
https://www.ncbi.nlm.nih.gov/pubmed/32382557
http://dx.doi.org/10.1155/2020/5462063
_version_ 1783528164766515200
author Zhou, Mengting
Hu, Naihua
Liu, Meichen
Deng, Ying
He, Linfeng
Guo, Chaocheng
Zhao, Xingtao
Li, Yunxia
author_facet Zhou, Mengting
Hu, Naihua
Liu, Meichen
Deng, Ying
He, Linfeng
Guo, Chaocheng
Zhao, Xingtao
Li, Yunxia
author_sort Zhou, Mengting
collection PubMed
description Nonalcoholic fatty liver disease, a type of metabolic syndrome, continues to rise globally. Currently, there is no approved drug for its treatment. Improving lifestyle and exercise can alleviate symptoms, but patients' compliance is poor. More and more studies have shown the potential of Polygoni Multiflori Radix (PMR) in the treatment of NAFLD and metabolic syndrome. Therefore, this paper reviews the pharmacological effects of PMR and its main chemical components (tetrahydroxystilbene glucoside, emodin, and resveratrol) on NAFLD. PMR can inhibit the production of fatty acids and promote the decomposition of triglycerides, reduce inflammation, and inhibit the occurrence of liver fibrosis. At the same time, it maintains an oxidation equilibrium status in the body, to achieve the therapeutic purpose of NAFLD and metabolic syndrome. Although more standardized studies and clinical trials are needed to confirm its efficacy, PMR may be a potential drug for the treatment of NAFLD and its complications. However, the occurrence of adverse reactions of PMR has affected its extensive clinical application. Therefore, it is necessary to further study its toxicity mechanism, enhance efficacy and control toxicity, and even reduce toxicity, which will contribute to the safe clinical use of PMR.
format Online
Article
Text
id pubmed-7193283
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-71932832020-05-07 A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix Zhou, Mengting Hu, Naihua Liu, Meichen Deng, Ying He, Linfeng Guo, Chaocheng Zhao, Xingtao Li, Yunxia Biomed Res Int Review Article Nonalcoholic fatty liver disease, a type of metabolic syndrome, continues to rise globally. Currently, there is no approved drug for its treatment. Improving lifestyle and exercise can alleviate symptoms, but patients' compliance is poor. More and more studies have shown the potential of Polygoni Multiflori Radix (PMR) in the treatment of NAFLD and metabolic syndrome. Therefore, this paper reviews the pharmacological effects of PMR and its main chemical components (tetrahydroxystilbene glucoside, emodin, and resveratrol) on NAFLD. PMR can inhibit the production of fatty acids and promote the decomposition of triglycerides, reduce inflammation, and inhibit the occurrence of liver fibrosis. At the same time, it maintains an oxidation equilibrium status in the body, to achieve the therapeutic purpose of NAFLD and metabolic syndrome. Although more standardized studies and clinical trials are needed to confirm its efficacy, PMR may be a potential drug for the treatment of NAFLD and its complications. However, the occurrence of adverse reactions of PMR has affected its extensive clinical application. Therefore, it is necessary to further study its toxicity mechanism, enhance efficacy and control toxicity, and even reduce toxicity, which will contribute to the safe clinical use of PMR. Hindawi 2020-04-20 /pmc/articles/PMC7193283/ /pubmed/32382557 http://dx.doi.org/10.1155/2020/5462063 Text en Copyright © 2020 Mengting Zhou et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Zhou, Mengting
Hu, Naihua
Liu, Meichen
Deng, Ying
He, Linfeng
Guo, Chaocheng
Zhao, Xingtao
Li, Yunxia
A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix
title A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix
title_full A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix
title_fullStr A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix
title_full_unstemmed A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix
title_short A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix
title_sort candidate drug for nonalcoholic fatty liver disease: a review of pharmacological activities of polygoni multiflori radix
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193283/
https://www.ncbi.nlm.nih.gov/pubmed/32382557
http://dx.doi.org/10.1155/2020/5462063
work_keys_str_mv AT zhoumengting acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT hunaihua acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT liumeichen acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT dengying acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT helinfeng acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT guochaocheng acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT zhaoxingtao acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT liyunxia acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT zhoumengting candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT hunaihua candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT liumeichen candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT dengying candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT helinfeng candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT guochaocheng candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT zhaoxingtao candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix
AT liyunxia candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix